Knight Therapeutics (GUD) AGM 2026 summary

Opening remarks and agenda

• Meeting held via live audio webcast to encourage broader shareholder participation and equal opportunity to engage and vote.

• Agenda included formal meeting proceedings, remarks from the CEO, and a Q&A session for shareholders.

Board and executive committee updates

• Directors nominated and re-elected for the ensuing year: Jonathan Ross Goodman, James C. Gale, Samira Sakhia, Robert N. Lande, Michael Tremblay, Nicolás Sujoy, and Janice Murray.

• Ernst & Young LLP appointed as auditors for 2026, with board authorized to fix their remuneration.

• Management team highlighted for experience across Canada and Latin America, with key roles in business development, finance, HR, regulatory, manufacturing, and marketing.

Financial performance review

• Achieved record revenues of CAD 452 million in 2025, up 24% from the prior year.

• Adjusted EBITDA reached CAD 73 million, a 26% increase year-over-year.

• Cash and marketable securities at year-end totaled CAD 95 million, with CAD 68 million in debt.

• Five-year revenue CAGR of 17% and adjusted EBITDA CAGR of 34%.

• Guidance for 2026 revenues set at CAD 490–510 million, with EBITDA targeted at 15% of adjusted revenues.